| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CONCISE REVIEW |
a University of Pittsburgh School of Medicine, Department of Molecular Genetics and Biochemistry, Pittsburgh, Pennsylvania;
b Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, Pennsylvania;
c Department of Neurology and GRECC, Pittsburgh VA Healthcare System, Pittsburgh, Pennsylvania, USA
Key Words. Herpes simplex virus • Gene therapy • Nervous system • Glioma • Neuropathy • Pain • Arthritis • Muscular dystrophy
Joseph C. Glorioso, Ph.D., University of Pittsburgh School of Medicine, Department of Molecular Genetics and Biochemistry, E1240 Biomedical Sciences Tower, Pittsburgh, Pennsylvania 15261, USA. Telephone: 412-648-8106; Fax: 412-624-8997; e-mail: glorioso{at}pitt.edu
Herpes simplex virus (HSV) is a neurotropic DNA virus. The viral genome is large (152 kb), and many genes are dispensable for viral function, allowing insertion of multiple or large transgene expression cassettes. The virus life cycle includes a latent phase, during which the viral genome remains as a stable episomal element within neuronal nuclei for the lifetime of the host, without disturbing normal function. We have exploited these features of HSV to construct a series of nonpathogenic gene therapy vectors that efficiently deliver therapeutic and experimental transgenes to neural and non-neural tissue. Importantly, transgene expression may be sustained long term; reporter gene expression has been demonstrated for over a year in the nervous system. This article discusses the generation of replication-defective HSV vectors and reviews recent studies investigating their use in several animal models of human disease. We have demonstrated correction or prevention of a number of important neurological phenotypes, including neurodegeneration, chronic pain, peripheral neuropathy, and malignancy. In addition, HSV-mediated transduction of non-neurological tissues allows their use as depot sites for synthesis of circulating and locally acting secreted proteins. New applications for this vector system include the genetic modification of stem cell populations; this may become an important means to direct cellular differentiation or deliver therapeutic genes systemically. Replication-defective HSV vectors are an effective and flexible vehicle for the delivery of transgenes to numerous tissues, with multiple applications.
This article has been cited by other articles:
|
|
 |
|
  H. Lauterbach, C. Ried, A. L. Epstein, P. Marconi, and T. Brocker Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity J. Gen. Virol., September 1, 2005; 86(9): 2401 - 2410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Trapp, J. von Einem, H. Hofmann, J. Kostler, J. Wild, R. Wagner, M. Beer, and N. Osterrieder Potential of Equine Herpesvirus 1 as a Vector for Immunization J. Virol., May 1, 2005; 79(9): 5445 - 5454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Selkirk Gene therapy in clinical medicine Postgrad. Med. J., October 1, 2004; 80(948): 560 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mata, J. C. Glorioso, and D. J. Fink Gene Transfer to the Nervous System: Prospects for Novel Treatments Directed at Diseases of the Aging Nervous System J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1111 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Acres, P. Beverley, and S. Scholl Tumor Immunology and the Battle of Waterloo Mol. Cancer Ther., June 1, 2002; 1(8): 651 - 655. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
